TMCnet News
Conference on 2nd Annual Vaccine Manufacturing (Conference Only)Katalin Abraham, Director, Infl uenza Vaccines, US Regulatory Affairs, GlaxoSmithKline Simon Hsu, Principal Scientist, Medimmune Andreas Nubert, VP Vaccines, IDT Biologika Jonathan Liu, Director Research and Vaccine Development, MedImmune John M Wood, Principal Scientist, Division of Virology, NIBSC Erdmann Rapp, Senior Scientist, Max Planck Institute, Germany Leo Posner, Director Regulatory Compliance, Charles River Laboratories Graham Clarke, Chief Executive offi cer, ImmBio Clifton E. McPherson, Director, Quality Control, Protein Sciences Kenneth Lee, Cell Culture Business Unit, Automation Partnership Ferruccio Messi, Founder, Cell Culture Technology Pierre Miniou, Director of Business Development, Vivalis Dear Colleague, The most important development in infl uenza vaccines over the next 5 years will be the diversifi cation of infl uenza manufacturing. New cell-based technologies will be used, and eventually replace existing egg-based manufacturing methods. Cell-culture-based technology is a major innovation in more than 50 years, and offers a robust and reliable alternative for the pharmaceutical industry in vaccine production. Cell culture-based infl uenza vaccines have shown that they are of high quality and meet the effi cacy requirements set out by regulatory authorities. However, challenges remains to meet the demands of the next seasonal campaign and to generate prototypes of pandemic vaccines for clinical trials. This conference will feature keynote addresses, presentations, case studies and interactive discussions on the benefi ts and challenges in using a cell culture approach to produce infl uenza vaccine. Please be sure to register your participation amongst the industry’s elite for this intensive two-day of learning, networking and exploiting business opportunities. I look forward to seeing you all in London Key Themes: • An overview of cell culture technology and the latest developments on cell-culture based vaccine production • Cell line selection and development • Mammalian cell culture processes for large scale operation • Glycan analysis in cell culture-based infl uenza vaccine production • Infl uence of host cell line and virus strain on the glycosylation pattern of viral Haemagglutinin • Safety and immunogenicity of injectable cell culture–derived infl uenza vaccine • Downstream processing parameters for purifi cation, fi lling, and packaging of the cell culture based vaccines • Flow cytometric monitoring of infl uenza virus infection • Validation of cell culture based processes & qualifi cation of associated equipment and facility • Analysing ventures of global vaccines manufacturers in the developing world • Regulatory issues associated with the development of cell-based infl uenza vaccine Who should attend? Presidents, Chief Executive Offi cers, Senior VPs, VPs, Global Heads, Chief Scientifi c Offi cers, Directors, Franchise Heads, Therapeutic Area Head, Professors, Account Managers, in:- • Vaccine equipment and manufacturing • Vaccine application development • Vaccinology and molecular biology • Proteomics, recombinant protein/DNA biotechnology • Infectious disease R&D • Pharmacovigilance and safety testing • Regulatory affairs • Strategic product development • Manufacturing/production • Chemistry manufacturing and controls • Strategic alliances • Clinical product resourcing • Supply outsourcing project management • Contract management • Process development • Drug discovery & delivery • Investment and venture capital Target Audience (News - Alert) - Industry Pharmaceutical companies, biopharmaceutical companies, Analysts, Consultant To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=125460&rt=Conference-on-2nd-Annual-Vaccine-Manufacturing-Conference-Only.html Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: [email protected] Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com Follow us on twitter: http://twitter.com/3bbharatbook As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments. [ Back To TMCnet.com's Homepage ] |